Loading
Loading
Research Overview
Soluble ACVR2B-Fc fusion protein acting as a decoy receptor; binds myostatin (GDF-8), activins, and GDF-11, preventing their activation of endogenous ACVR2B on skeletal muscle cells and removing the braking signal on muscle hypertrophy.
ACE-031 was developed by Acceleron Pharma as a therapeutic candidate for muscle-wasting diseases including Duchenne muscular dystrophy. Its mechanism involves competitive inhibition of myostatin — a TGF-β superfamily ligand that limits muscle growth — by acting as a soluble decoy receptor that 'traps' myostatin and related ligands before they can bind to endogenous ACVR2B on muscle cell surfaces.
Phase 1 clinical trials in healthy postmenopausal women demonstrated significant lean mass increases within weeks of administration, validating the myostatin-inhibition hypothesis. However, Phase 2 development in Duchenne patients was halted in 2013 following adverse events including epistaxis (nosebleeds) and telangiectasias, attributed to off-target inhibition of non-myostatin TGF-β ligands with vascular roles.
ACE-031 differs from other myostatin-targeting approaches by blocking multiple TGF-β superfamily ligands simultaneously — not only myostatin but also activins and GDF-11 — which contributes both to its potent muscle-promoting effects and its safety signal liability.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, ace-031 (acvr2b-fc) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
ACE-031 (ACVR2B-Fc) research is most relevant to protocols examining:
Myostatin inhibition and muscle wasting disease research (DMD, SMA)
ACVR2B decoy receptor biology studies
Muscle hypertrophy ceiling and GDF-8 pathway investigations
Researchers studying activin/myostatin ligand trapping approaches
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~10–15 days). Review data, confirm baseline recovery before any repeat protocol.
Soluble ACVR2B-Fc fusion protein acting as a decoy receptor; binds myostatin (GDF-8), activins, and GDF-11, preventing their activation of endogenous ACVR2B on skeletal muscle cells and removing the braking signal on muscle hypertrophy.
| Parameter | Value |
|---|---|
| Dose range | 1–3 mg/kg (trial range only |
| Alt. dose 2 | no community protocol) |
| Schedule | Weekly to monthly (trial range) |
| Route | Subcutaneous |
| Half-life | ~10–15 days |
observed in clinical trials)
high-risk profile
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.